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Abstract
Background: TRAIL is considered as a promising anti-cancer agent, because of its ability to induce apoptosis in cancer 
but not in most normal cells. However, growing evidence exist that many cancer cells are resistant to its apoptotic 
effects. SCLC is a typical example of tumor entity where TRAIL monotherapy is not efficient.
Results: We demonstrated that doxorubicin and etoposide markedly sensitized SCLC cells expressing caspase-8 to 
apoptotic effects of TRAIL. The drug-mediated sensitization of these cells was associated with increase of surface and 
total DR5 protein level, specific cleavage of cFLIPL, decrease of cFLIPS level, and a strong activation of caspase-8. The 
involvement of mitochondria-mediated pathway was demonstrated by enhanced Bid cleavage, Bax activation, and 
cytochrome c release. Activation of caspase-8 induced by combined treatment was shown to occur upstream of 
mitochondria and effector caspases.
Conclusions: Our results highlight significant applicability of doxorubicin and etoposide in sensitization of SCLC cells 
expressing caspase-8 to treatment with TRAIL.
Background
Lung cancer (LC) is a major cause of cancer deaths in the
Western world. Based on the histo-pathological features,
LC is divided into small cell lung carcinoma (SCLC), and
non-small cell lung carcinoma (NSCLC), which account
for 25 and 75% of bronchogenic carcinomas, respectively.
I n  c o n t r as t  t o  NSCL C,  SCL C  is  c h a r a ct e r iz ed  b y  r e l a -
tively high sensitivity to treatment with anticancer drugs
and radiation. However, despite the initial responsive-
ness, relapses occur in most cases, accompanied by the
fast development of severe resistance to treatments dur-
ing the course of disease. SCLC represents a highly malig-
nant and particularly aggressive form of cancer, with early
and widespread metastases, and poor prognosis. Mecha-
nisms responsible for the intrinsic and acquired resis-
tance to treatment involve the defects/dysregulations of
the apoptotic programme [1,2]. The avoidance of apopto-
sis is considered as one of the hallmarks of cancer cells,
and represents a significant clinical problem. Therefore,
elucidation of the mechanisms and molecules responsible
for the resistance is essential for proper targeting of anti-
cancer therapy.
The tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL), a member of TNF family, is
particularly interesting because of its unique ability to
induce cancer cell death while sparing the most of normal
cells. This implies its potential promise as an anti-cancer
agent [3]. TRAIL can interact with different receptors.
Only two of them, namely, death receptors (DR) contain
apoptosis-related death domain (DD): DR4 (TRAIL-R1)
and DR5 (TRAIL-R2). Decoy receptors DcR1 (TRAIL-
R 3 )  a n d  Dc R 2  (T RAIL - R 4 )  e i t h e r  l a c k  o r  po s s e s  t ru n -
cated DD and are, therefore, not able to transmit apop-
totic signal. Osteoprotegerin (OPG, TRAIL-R5) is a
soluble receptor with the lowest afinity to TRAIL [4].
TRAIL binding to DR4 and DR5 results in triggering of
the extrinsic pathway, initiated by formation of the death-
inducing signalling complex (DISC) consisting of Fas-
associated DD protein (FADD) and pro-caspase-8. Acti-
vation of caspase-8 at the DISC level plays a crucial role
in the DR-mediated pathway, and can be efficiently regu-
lated by its competitive inhibitor cFLIP (FLICE-like
inhibitory protein). Caspase-8 activation is followed by
cleavage of effector caspases and apoptosis execution
(characteristic for type I cells). In some cases, caspase-8
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can also cleave Bid, which is responsible for translocation
of apoptotic signal to mitochondria. Subsequent amplifi-
cation of the death signal at the level of these organelles is
essential in so-called type II cells [5,6].
TRAIL triggers apoptosis in a broad spectrum of cancer
cell lines in vitro and in vivo [7,8]. However, failure to
undergo apoptosis in response to TRAIL has been dem-
onstrated in majority of SCLC cells [9,10]. Significant
perturbances of apoptosis programme such as downregu-
lation/absence of some proapoptotic proteins and/or
overexpression of anti-apoptotic proteins have been
shown to be a characteristic feature of SCLC cells [11].
The higher rates of loss of expression of caspase-8, cas-
pase-10, DR4, DR5, Fas, and FasL have been found in
SCLC compared to NSCLC cells [9,12]. A relationship
between the inactivation of some DISC components and
Myc oncogene amplification, which is a common event in
SCLC, has also been reported [9].
Majority of chemotherapeutic agents are typical activa-
tors of mitochondria-mediated (intrinsic) apoptotic path-
way, where release of cytochrome c from mitochondrial
intermembrane space is followed by formation of apopto-
some complex (cytochrome c, Apaf-1, dATP, pro-cas-
pase-9), activation of initiator caspase-9 and downstream
effector caspases. The described events can be effectively
modulated by pro-apoptotic (e.g. Bid, Bax, Bak) and/or
anti-apoptotic (e.g. Bcl-2, Mcl-1, Bcl-XL) members of Bcl-
2 family [13]. Caspase-2 has been shown as an important
link between DNA damage and the engagement of the
mitochondrial pathway [14].
The clinically relevant concentrations of chemothera-
peutic drugs might restore the apoptotic response to
TRAIL in various cancer cells through different mecha-
nisms and, therefore, sensitize these cells to TRAIL treat-
ment. Among them, upregulation of the DRs, facilitation
of DISC formation, downregulation of anti-apoptotic
proteins, enhancement of activation of mitochondrial
pathway and caspase cascade are particularly interesting
[15,16]. However, respective data concerning SCLC treat-
ments are still missing. The usual therapeutic regimes
used for this type of cancer include e.g. doxorubicin,
etoposide or cisplatin. As TRAIL monotherapy has been
shown to be ineffective in SCLC, in present study we
explored the potential use of combination of TRAIL and
doxorubicin or etoposide in order to provide a tool for
triggering apoptosis in resistant cancer cells.
Materials and methods
Cell culture and treatments
Human SCLC cell lines - H69 (ECACC), H82 (ATCC),
U1285, U1690, and U1906 [17] were grown in RPMI 1640
medium supplemented with 10% of heat-inactivated fetal
bovine serum (FBS), glutamine (2 mM), penicillin (100 U/
ml) and streptomycin (100 μg/ml) (all from Gibco) in
37°C, 5% CO2 and 95% humidity. Twenty-four hours after
seeding, cells were treated with human recombinant
Killer TRAIL (provided by Dr. L. Andera), doxorubicin
(Sigma), etoposide (Vepesid, Bristol-Myers), PKC412
(CGP41251, Novartis), cycloheximide (Sigma), pan-cas-
pase inhibitor z-VAD-fmk (Enzyme Systems Products) or
vehicle (DMSO) for the time points and concentrations
indicated in figure legends.
Surface TRAIL receptor expression
The level of surface TRAIL receptors was detected in
cells after incubation with specific antibodies using flow
cytometry [18]. Briefly, after washing with PBS + 5% FBS,
cells were incubated (20 minutes, 4°C) with primary anti-
body (anti-TRAIL-R1 to -4 flow cytometry set, Axorra;
HS101, HS201, HS301, HS402 antibodies, respectively).
C e lls  we r e  t he n was hed t wic e ,  a nd in cuba t ed ( 20 m in,
4°C) with secondary antibody (FITC-conjugated goat
anti-mouse IgG1, ALX-211-200, Axorra or AlexaFluor-
488-conjugated donkey anti-mouse-IgG, A21202, Molec-
ular Probes). After washing twice, the cells were stained
(15 min, 4°C) with 7-AAD (1 μg/ml, Molecular Probes)
and analyzed using flow cytometry (FACScan, Becton
Dickinson). The 7-AAD negative cells were subjected to
receptor analysis (Cell Quest software). Results are
expressed as histograms (green fluorescence indicating
the amount of the receptor present at the cell surface ver-
sus cell counts), and related to appropriate control lack-
ing the specific primary antibody.
Analysis of Bax activation
Cells were washed in PBS, fixed in 1% paraformaldehyde
(10 minutes, 4°C), washed again, and incubated (30 min,
4°C) with mouse anti-Bax antibody (BD556467, Becton
Dickinson) diluted in PBS containing 1% BSA and 0.1%
saponin. After additional washing, cells were incubated
(30 min, 4°C) with AlexaFluor-488-conjugated donkey
anti-mouse IgG secondary antibody (A21202, Molecular
Probes) diluted in PBS + 1% BSA + 0.1% saponin, washed
twice, and resuspended in PBS. For each sample, controls
lacking the specific primary antibody were prepared.
Analysis was performed using flow cytometer (FACScan,
Becton Dickinson) and CellQuest software. Ten thousand
cells per sample were analysed and the results were
expressed as percentage of cells with active Bax.
Analysis of mitochondrial membrane potential (MMP)
After washing in PBS, cells were incubated (20 minutes)
in HBSS with 25 nM of tetramethylrhodamine ethyl ester
perchlorate (TMRE, Molecular Probes), washed twice
with HBSS, and analysed (2 × 104 cells per sample) by
flow cytometry (FACScan, Becton Dickinson). Forward
and side scatters were used to gate the viable cell popula-Vaculova et al. Molecular Cancer 2010, 9:87
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tion. The data were evaluated using Cell Quest software
as a percentage of the cells with decreased MMP.
Caspase activity assay
Cells were lysed in appropriate lysis buffer, incubated
with caspase-3, caspase-8 or caspase-2 substrates and
analysed as described previously [19]. The values of cas-
pase activity were related to the total protein amount.
Caspase activity was expressed as a fold-increase to
appropriate control.
Immunoblotting
Cells were lysed in Complete lysis buffer (Roche) with
protease inhibitor cocktail (PIC, Complete-M, Roche).
The protein concentration was determined in samples
(BCA protein assay, Pierce), which were mixed with
Laemmli buffer and subjected to SDS-PAGE and western
blotting [19]. For immunodetection, following antibodies
were used: anti-cleaved PARP (CS9546), anti-cleaved
lamin A (CS2036), anti-cleaved caspase-3 (CS9661), anti-
Bid (CS2002) (Cell Signaling Technology), anti-DR4
(D3813), anti-DR5 (D3938), anti-Mcl-1 (M8434) (Sigma),
anti-caspase-10 (M059-3, MBL), anti-FLIP (NF6, 804-
428, Axorra), anti-caspase-2 (BD611022), anti-FADD
(BD556402), anti-cytochrome c  (BD556433), and anti-
Bax (BD556467) (Becton Dickinson), anti-survivin
(ab469, Abcam), anti-caspase-8 (provided by Prof. P.
Krammer), anti-Bcl-2 (sc492), anti-Bcl-XL (sc-634) (Santa
Cruz Biotechnology). The recognized proteins were
detected using horseradish peroxidase-labelled second-
ary antibodies: anti-mouse IgG (31430, Pierce), anti-rab-
bit IgG (31460, Pierce), and enhanced
chemiluminescence kit (Western blot detection reagent,
GE Healthcare UK Limited). An equal loading was veri-
fied using anti-β-actin (A2066, Sigma), anti-G3PDH
(2275, Trevingen) or anti-TOM40 (sc-11414, Santa Cruz
Biotechnology, for mitochondrial fraction) antibodies.
For detection of cytosolic and mitochondrial cytochrome
c and Bax, the cells were washed twice with PBS, incu-
bated (5 min, 4°C) in buffer (250 mM sucrose, 70 mM
KCl, 100 μg/ml digitonin in PBS), centrifuged (5 min,
7000 g), and the supernatant was collected (cytosolic
fraction). Mitochondrial fraction was prepared by lysis of
the pellet in Complete Lysis-M buffer with PIC (Roche).
cFLIP and caspase-8 overexpression
Twenty four hours after seeding, cells were transfected
with DNA:Lipofectamine 2000 (Invitrogen) mixture at
ratio 2 μg:1 μl according to manufacturer's instructions.
Following next 24 h, medium was exchanged and the cells
were treated (8 or 24 h) with TRAIL (100 ng/ml), doxoru-
bicin (1 μM) or their combination. The following plas-
mids were used: pcDNA3 (Invitrogen), pcDNA3-Flag-
cFLIPS (provided by Prof. P. Krammer and Dr I. Lavrik),
pcDNA-MACH alpha1 (provided by Prof. D. Wallach),
pMSCV-IRES-GFP, and cFLIPL-pMSCV-IRES-GFP (pro-
vided by Dr A. Grandien).
cFLIP and caspase-8 siRNA experiments
Three different specific siRNAs were used to downregu-
late (a) both long and short cFLIP, (b) the long form, or (c)
the short form only. The non-targeting siRNA was used
as control. All the siRNAs were synthesized by Qiagen
according to Galligan et al. [20]. The siRNA was diluted
in 100 μl of Opti-MEM I medium (Gibco), and 1 μl of
Lipofectamine 2000 reagent (Invitrogen) was added to
other 100 μl of OptiMEM I medium. Diluted siRNA and
Lipofectamine 2000 were then mixed and incubated for
20 min. Transfection complexes were added (200 μl per
well) to cells 24 h after seeding in 12 well plates. The final
concentration of siRNA was 100 nM. After 24 h, the
medium was exchanged, and cells were treated (24 h)
with TRAIL (100 ng/ml). For caspase-8 siRNA transfec-
tion, the same experimental protocol was used, and the
cells were treated with TRAIL and/or doxorubicin 48 h
after transfection. Caspase-8 siRNA (L-003466-00) and
control siRNA (D-001810-10) were obtained from Dhar-
macon.
MTS assay
Cells were seeded in 96-well plates at a density of 104 cells
per well and 24 h later treated with various concentra-
tions of the drugs. After next 24 h, CellTiter 96 AQueous
MTS Reagent Solution (Promega) was added to each well
according to the manufacturer's instructions, and in 1 h
the cell viability was determined by measuring the absor-
bance at 490 nm using Labsystems Multiscan MCC/340
plate reader.
Analysis of nuclear morphology
Cells were washed in PBS, fixed in ethanol (70%), stained
(30 min) with 4,6-diamidino-2-phenyl-indole (DAPI,
Fluka, 1 μg DAPI/ml ethanol) and mounted in Mowiol.
The percentage of apoptotic cells (with chromatin con-
densation and fragmentation) was calculated from a total
number of 200 cells using LSM 510 META spectral laser
scanner microscope (Zeiss).
Analysis of DNA content
For DNA analysis, cells were fixed in 70% cold ethanol
overnight, washed, incubated 1 h at 37°C with RNAse A
(100 μg/ml), and exposed to PI (50 μg/ml) in phosphate-
buffered saline (pH 7.4) for 30 min. The cells were ana-
lyzed by flow cytometry (FACScan, Becton Dickinson)
and CellQuest software. The cell death was monitored by
evaluation of percentage of cells with subdiploid amount
of DNA.Vaculova et al. Molecular Cancer 2010, 9:87
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Statistical evaluation
The results of three independent experiments were
expressed as the means ± S.E.M. Statistical significance (p
< 0.05) was determined by one-way ANOVA followed by
Tukey test or by non-parametric Mann-Whitney test.
Results
SCLC cell lines are resistant to TRAIL-induced apoptosis, 
and differ in the expression of proteins involved in TRAIL 
signaling
All five SCLC cell lines studied - H69, H82, U1285,
U1690, U1906 - were resistant to apoptotic effects of
TRAIL (100 ng/ml), as demonstrated by the absence of
PARP cleavage (Figure 1A) or caspase-3 processing (not
shown) after 72 h of treatment. Expression of selected
proteins important in TRAIL signaling was analyzed in
untreated cell lines. We showed that only 1 (U1906) out
of 5 cell lines expressed DR4 at the surface, and 4 out of 5
cell lines (except for H69) did express DR5. While no sur-
face DcR1 was present in any of cell lines, DcR2 was
always detected (flow cytometry, Figure 1B). Despite its
absence at the cell surface, all cell lines expressed (at vari-
ous amounts) DR4 protein. The significant differences at
the level of total DR5 protein were apparent among cell
lines, being highest in U1906, not detectable in H69, and
low in U1690 cells, which correlated with the cell surface
levels. In spite of the relatively high amount of total DR5,
its lower level was detected at the surface of U1285 cells
(Figure 1C). While pro-caspase-8 was present in U1285
and U1690 cells, it was not detected in H82, H69, and
U1906 cells. All cell lines expressed a relatively high level
of pro-caspase-2, most abundantly in U1285 and U1690
cells. No pro-caspase-10 was detected in any of them
(Figure 2A). All five cell lines expressed FADD protein
(especially U1690). A relatively high level of long and
short cFLIP form was apparent in H69, U1690, and
U1906 cells. Both cFLIP forms were absent in H82 cells.
In U1285 cells, only a low level of cFLIPL was detected
(Figure 2B). The survivin expression differed significantly
among the cell lines, being the highest in H82, U1285,
and U1906. A relatively high level of Mcl-1 was found in
the SCLC cells studied (except for H69 cells). Bcl-2 pro-
tein was detected in 2 out of the 5 cell lines (Figure 2C).
Doxorubicin and etoposide sensitize SCLC cells expressing 
caspase-8 protein to TRAIL-induced apoptosis
Based on the results presented in Figures 1 and 2, two cell
lines - U1690 and U1285 - were selected for further inves-
tigations. Both expressed pro-caspase-8 protein, an
essential molecule for TRAIL apoptotic signaling, and a
similar level of cell surface DR5. While we showed a
strong induction of apoptosis (caspase-8, -3, and PARP
cleavage) in U1690 and U1285 cells treated (24 h) with 1
μM PKC412 (positive control), the cells did not respond
even to a relative high dose of TRAIL (1 μg/ml) (Figure
3A). In order to be sensitized to TRAIL-induced apopto-
sis, cells were co-treated with doxorubicin or etoposide.
To determine a suitable concentration of chemotherapeu-
tic drug, the dose response to this agent was investigated
using MTS cytotoxicity test (data not shown). Two to
three concentrations of the drugs (with low or no cyto-
toxicity) were then selected to be combined with TRAIL
(100 ng/ml). When U1285 cells were simultaneously
treated (24 h) with TRAIL and doxorubicin (1 or 2 μM), a
dose-dependent potentiation of apoptosis (enhanced
PARP and caspase-3 cleavage) was achieved compared to
agents used alone (Figure 3B and not shown). Similarly, a
strong PARP cleavage was detected upon co-treatment of
U1690 cells with TRAIL and doxorubicin (0.5 or 1 μM) as
well as TRAIL and etoposide (2.5 or 5 μM) (Figure 3B, C).
To investigate the mechanisms involved in sensitization
of SCLC cells expressing caspase-8 to apoptosis induced
by combined treatment with TRAIL and chemotherapeu-
tic drugs, treatment with doxorubicin was chosen and
U1690 cells were subjected to more detailed study. A par-
ticular attention was paid to the involvement of caspases,
mitochondria, and several important molecules of
TRAIL signaling pathway. A substantial cleavage of pro-
caspase-8 and PARP was detected in cells co-treated (24
h) with doxorubicin (1 μM) and different doses of TRAIL
(10-250 ng/ml) (Figure 3D), together with increase in cas-
pase-2, -3 activity (Figure 3E) and processing (not
shown). No changes of caspase-2, -3 activity (compared
to control) were detected in cells treated with TRAIL, and
a slight enhancement was observed after doxorubicin
administration (Figure 3E). Pretreatment with z-VAD-
fmk prevented the cooperative apoptotic effect of TRAIL
and doxorubicin as demonstrated by inhibition of charac-
teristic apoptotic changes in the nucleus (Figure 4A), and
blockage of PARP and lamin A cleavage (Figure 4B). In
the presence of z-VAD-fmk, TRAIL- and doxorubicin-
induced processing of caspase-2 and -3 was completely
blocked. However, the decrease of pro-caspase-8 level,
and generation of its 41/43, but not 18 kDa fragments
were still detected (Figure 4B).
The combination of TRAIL and doxorubicin induced a
significant decrease of full length Bid protein level,
accompanied by increased amount of its cleavage product
tBid (Figure 4C), a slight decrease of Bcl-XL, but no signif-
icant changes of Bcl-2 or Mcl-1 protein levels compared
to agents used alone (Figure 4C). Significant decrease of
the survivin level was also detected in response to doxo-
rubicin alone or its combination with TRAIL (Figure 4C).
During 24 h treatment with TRAIL and doxorubicin, an
increased translocation of Bax to mitochondria was
observed (Figure 4C and not shown), which was associ-
ated with an increased percentage of cells with active Bax
compared to TRAIL-treated (no Bax activation) or doxo-Vaculova et al. Molecular Cancer 2010, 9:87
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Figure 1 SCLC cell lines are resistant to TRAIL treatment and differ in expression of TRAIL receptors. (A) Cleavage of PARP was analyzed in H69, 
H82, U1285, U1690, and U1906 cells treated (72 h) with TRAIL (100 ng/ml). An equal loading was verified using anti-β-actin antibody. (B) Surface ex-
pression of DR4, DR5, DcR1, and DcR2 in these cells (flow cytometry, for details see Materials and methods, black lines - controls lacking primary anti-
body). (C) Total level of DR4 and DR5 in these cells. An equal loading was verified using anti-β-actin antibody. All results are representative of three 
independent experiments.
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rubicin-treated (only low Bax activation) cells (Table 1).
The redistribution of cytochrome c from mitochondria to
cytosol was demonstrated after 12 h (and especially after
16, 20, and 24 h) of incubation with TRAIL and doxorubi-
cin (Figure 4D). Treatment of U1690 cells with TRAIL
and doxorubicin also induced significant increase in
number of cells with decreased MMP, and with subdip-
loid DNA content (Table 1). To explore whether combi-
nation of doxorubicin or etoposide with TRAIL also
exerted a cytotoxic effect in cells lacking caspase-8, the
number of U1906 cells with subdiploid amount of DNA
and decreased MMP was analyzed following the above
mentioned treatments (Figure 4E). As expected, both
drugs did not sensitize U1906 cells to TRAIL, demon-
strating the requirement of caspase-8 for sensitization of
SCLC cells to TRAIL.
During the course of 24 h incubation of U1690 cells
with TRAIL and doxorubicin, the changes of the expres-
sion or cleavage of several important proteins involved in
TRAIL signaling were examined. A decrease of pro-cas-
pase-8 level, and accumulation of its 41/43 and 18 kDa
fragments were apparent after 8 h, and particularly after
12 h (Figure 5A), accompanied by a significant increase of
caspase-8 activity (data not shown) in TRAIL and doxo-
rubicin-treated cells compared to the individual agents.
Twenty-four hours of cell incubation with TRAIL and
Figure 2 SCLC cell lines significantly differ in expression of pro-
teins involved in TRAIL signaling. The level of (A) pro-caspase-8, -2, -
10, (B) FADD, cFLIPL, cFLIPS, and (C) survivin, Mcl-1, and Bcl-2 proteins 
in H69, H82, U1285, U1690, and U1906 cells. An equal loading was con-
trolled using anti-β-actin antibody. Jurkat cells were used as a positive 
control for expression of caspase-10. Results are representative of three 
independent experiments.
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Figure 4 The role of caspases and mitochondria in apoptosis induced by combination of TRAIL and doxorubicin in U1690 and U1906 SCLC 
cell lines. (A) U1690 cells (%) with characteristic apoptotic nuclear morphology (DAPI staining) after pre-treatment (1 h) with z-VAD-fmk (3 μM) or 
vehicle (DMSO), and subsequent treatment (24 h) with TRAIL (100 ng/ml), doxorubicin (1 μM), or their combination. Results are means ± S.E.M. of three 
independent experiments. Statistical significance: P < 0.05, (*) versus control, (+) versus TRAIL, (x) versus doxorubicin, (o) versus appropriate sample 
without z-VAD-fmk. (B) Cleavage of PARP, caspase-8 (12 h) or lamin A, caspase-2, and caspase-3 (24 h) in U1690 cells treated as indicated in (A). An 
equal loading was verified using G3PDH or anti-β-actin antibody. (C) The cleavage of Bid, level of Bcl-2, Bcl-XL or Mcl-1 protein (whole cell lysates), and 
Bax translocation (mitochondrial fraction) in U1690 cells treated (24 h) with TRAIL (100 ng/ml), doxorubicin (1 μM) or their combination. An equal load-
ing was verified using anti-β-actin (whole cell lysates) or anti-TOM (mitochondrial fraction) antibody. (D) The release of cytochrome c into the cyto-
plasm of U1690 cells treated (12, 16, 20, 24 h) with TRAIL (100 ng/ml), doxorubicin (1 μM) or their combination. An equal loading was verified using 
anti-G3PDH antibody. Results are representative of three independent experiments. (E) Percentage of U1906 cells with subdiploid DNA content and 
decreased mitochondrial membrane potential after treatment (24 h) with TRAIL (100 ng/ml), doxorubicin (0.5 μM), etoposide (2.5 μM) or their combi-
nation with TRAIL.
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doxorubicin resulted in a complete loss of pro-caspase-8,
and disappearance of its specific cleavage fragments due
to their rapid degradation. A cleavage of cFLIPL to its 43
kDa fragment was detected during 8-24 h of combined
treatment, and 12-24 h of doxorubicin administration. A
decrease of cFLIPS after 12 h, and its almost complete loss
after 24 h of incubation with TRAIL and doxorubicin or
doxorubicin alone was observed. During the first 12 h, no
changes of FADD level were detected after any type of
treatment, but 24 h incubation of cells with TRAIL and
doxorubicin resulted in significant decrease of FADD.
Doxorubicin was responsible for significant up-regula-Vaculova et al. Molecular Cancer 2010, 9:87
http://www.molecular-cancer.com/content/9/1/87
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tion of the total level of two DR5 protein forms, starting
from 8 h in both doxorubicin- or TRAIL and doxorubi-
cin-treated cells (Figure 5A). A significant doxorubicin-
induced increase of the surface DR5, but not DR4 was
also found using flow cytometry (Figure 5B and not
shown). In order to demonstrate a key role of caspase-8,
cells were transfected with control or caspase-8 siRNA
and then treated (11 or 16 h) with TRAIL and/or doxoru-
bicin. Downregulation of caspase-8 resulted in significant
reduction of apoptosis, decreased PARP cleavage and
caspase-2, -3 processing in TRAIL and doxorubicin-
treated cells (Figure 5C). Markedly, restoration of cas-
pase-8 expression after caspase-8 siRNA-mediated
silencing re-sensitized U1690 cells to undergo apoptosis
induced by combination of doxorubicin with TRAIL (Fig-
ure 5D).
Several approaches were used to study the role of cFLIP
in regulation of TRAIL-induced apoptosis. First, the cells
were transfected with siRNA targeting cFLIPL  and/or
cFLIPS. Simultaneous elimination of the two cFLIP forms
sensitized cells to apoptosis induced by TRAIL (100 ng/
ml, 24 h), as demonstrated by enhanced cleavage of PARP,
caspase-3, and increase of number of cells with apoptotic
nuclear morphology, compared to control siRNA-trans-
fected cells (Figure 6A). To be able to distinguish between
the role of cFLIPL and cFLIPS, another set of experiments
was carried out using two siRNAs selectively targetting
either cFLIPL, or cFLIPS. In this case, more intensive
TRAIL-induced apoptotic response (increased PARP
cleavage) was apparent in cells transfected with cFLIPL
siRNA (Figure 6B). Second, CHX was used to eliminate
cFLIPL/S in U1690 cells, which was associated with their
sensitization to TRAIL-induced apoptosis shown by
enhanced cleavage of PARP and caspase-8 (Figure 6C).
Third, the response to TRAIL and doxorubicin was
examined following cell transfection with cFLIPL  or
cFLIPS vectors. Overexpression of cFLIPL or cFLIPS ren-
dered cells less sensitive to apoptosis induced by combi-
nation of TRAIL and doxorubicin (Figure 6D).
Discussion
SCLC is a tumour entity where TRAIL monotherapy is
not efficient. The loss of some DISC components, associ-
ated with inactivation of DR pathway make sensitization
of the SCLC cells to TRAIL very difficult [9,10,12,21].
Caspase-8 is frequently silenced in SCLC and other
tumours of neuroendocrine origin, usually by aberrant
promoter methylation [22,23]. According to our results, 3
out of 5 studied SCLC cell lines were deficient for cas-
pase-8, all lacked caspase-10, and only 1 cell line
expressed surface DR4. Previously, restoration of cas-
pase-8 expression by demethylation or gene transfer was
shown to sensitize neuroblastoma cells to DR-mediated
apoptosis [23]. It has also been suggested that the resis-
tance of SCLC cells lacking caspase-8 to TRAIL might be
partially eliminated by combination of demethylation
agents and treatment with IFNγ [10]. However additional
studies should be performed in order to elucidate how
general this phenomenon is.
Notably, we and others found that caspase-8 expressing
SCLC cells are also resistant to TRAIL-induced apopto-
sis. Therefore, we aimed to investigate whether the cyto-
t o x i c  e f f e c t s  o f  T R A I L  i n  S C L C  c o u l d  b e  r e s t o r e d  b y
doxorubicin or etoposide, the conventionally used drugs
for treatment of SCLC, and what are the mechanisms
responsible for apoptosis resistance of caspase-8 express-
ing SCLC cells. Our results demonstrated that combina-
tion of these drugs with TRAIL might significantly
improve efficiency to kill this type of SCLC cells as com-
pared with drugs used alone.
The presence of TRAIL death receptors DR4 and/or
DR5 at the cell surface is not always sufficient to trigger
apoptosis and that might be due to an existence of the
defects of intracellular signaling pathways or high expres-
sion of inhibitory proteins. Upregulation of DRs follow-
ing treatment with chemotherapeutic agents has been
demonstrated in some cancer cells, while no effects were
apparent in others [24,25]. This upregulation has been
shown to be responsible for the synergistic action of
TRAIL and chemotherapy in several cell lines [26-28]. In
Table 1: Percentage of U1690 cells with decreased mitochondrial membrane potential, active Bax and subdiploid DNA 
content. 
% of cells Control TRAIL Doxorubicin TRAIL+Doxorubicin
Decreased MMP 2.3 ± 0.6 2.2 ± 0.7 13.4 ± 1.8 * 29.8 ± 6.3 *+x
Active Bax 1.5 ± 0.9 2.8 ± 0.4 11.9 ± 3.5 * 44.1 ± 5.3 *+x
Sub-G1 4.9 ± 0.6 5.2 ± 0.5 21.9 ± 3.4 +* 40.4 ± 1.7 *+x
Cells were treated (24 h) with TRAIL (100 ng/ml), doxorubicin (1 μM) or their combination. Results are means ± S.E.M. of three independent 
experiments. Statistical significance: P < 0.05, (*) versus control, (+) versus TRAIL, (x) versus doxorubicin. MMP - mitochondrial membrane 
potential.Vaculova et al. Molecular Cancer 2010, 9:87
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Figure 5 Time-dependent changes in the expression level of apical proteins involved in TRAIL signaling pathway and an esesential role of 
caspase-8 in apoptosis induced by combined treatment of doxorubicin and TRAIL in U1690 cells. (A) Cleavage of PARP, caspase-8, cFLIPL, and 
the level of cFLIPS, FADD, and DR5 in U1690 cells treated (4, 8, 12, 24 h) with TRAIL (100 ng/ml), doxorubicin (1 μM) or their combination. An equal 
loading was controlled using anti-G3PDH antibody. (B) The surface level of DR5 in U1690 cells untreated or treated (24 h) with doxorubicin (1 μM), 
detected by flow cytometry, using specific primary mouse anti-DR5 antibody, followed by anti-mouse secondary AlexaFluor-488-conjugated anti-
body. Cells incubated with secondary antibody alone (marked by asterisk) were used to check the background fluorescence. Results are representative 
of three independent experiments. (C) Cleavage of PARP or caspase-8, -3, -2 in U1690 cells transfected (48 h) with control or caspase-8 siRNA, and then 
treated (11 or 16 h) with TRAIL (100 ng/ml), doxorubicin (1 μM) or their combination. An equal loading was verified using anti-G3PDH antibody. An 
asterisk indicated unspecific antibody staining. (D) Cleavage of PARP and level of caspase-8 in U1690 cells transfected (48 h) with control or caspase-
8 siRNA, then transfected with pcDNA-MACH alpha 1 (caspase-8) expressing vector (200 ng) and treated (16 h) with TRAIL (100 ng/ml), doxorubicin 
(1 μM) or their combination. An equal loading was verified using anti-G3PDH antibody.
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our experiments, untreated U1690 cells expressed a rela-
tively low level of DR5 and no DR4 at the surface. Signifi-
cant increase of surface DR5, but not DR4 was observed
after treatment with doxorubicin, and no significant
changes of DcRs level (not shown) as has been demon-
strated by others [29]. Our results, therefore, suggest that
DR5 plays an exclusive role in mediation of signals trig-
gered by TRAIL in these cells. Furthermore, relocalisa-
tion and clustering of DR5 within ceramide-enriched
membrane platforms has been reported to affect TRAIL-
induced apoptosis in cells treated with doxorubicin [30].
Similar changes at the level of plasma membrane might
be also involved in enhancement of TRAIL apoptotic sig-
naling in SCLC cells.
Caspase-8 activation at the DISC proceeds through two
subsequent cleavage steps that can be effectively regu-
lated by cFLIP proteins. While cFLIPL allows the first
cleavage of pro-caspase-8, cFLIPS can completely inhibit
both of them [31]. cFLIP is known to play an important
role in regulation of TRAIL- and chemotherapy-induced
apoptosis [20,32,33]. Doxorubicin-induced downregula-
tion of cFLIPS contributed to sensitization of prostate
cancer cells to apoptotic effects of TRAIL [34,35]. Signifi-
cant decrease of cFLIPL/S level and appearance of specific
p43-cFLIPL  fragment following doxorubicin or TRAIL
and doxorubicin treatment indicated their involvement in
modulation of apoptotic response of U1690 cells to
TRAIL. The role of p43-cFLIPL in regulation of caspase-8
activation is still controversial, as both anti- and pro-
apoptotic functions of this fragment have been demon-
strated [36,37]. CHX-mediated downregulation of cFLIP
level previously published also in some other cancer cell
types [38,39], resulted in sensitization of U1690 cells to
TRAIL-induced apoptosis, showing that resistance of
these cells may be at least partially induced by newly syn-
thesized proteins acting upstream of caspase-8. The
siRNA-mediated downregulation of cFLIPL/S sensitized
U1690 cells to TRAIL-induced apoptosis, although to a
significantly lesser extent than combination of TRAIL
with doxorubicin or etoposide. Moreover, overexpression
of cFLIPL or cFLIPS only partially protected the cells from
apoptosis induced by this combinatory treatment.
Recently, it has also been shown that silencing of cFLIP
induced caspase-8 activation via increased co-localisation
of DR5 and ceramide, and significantly enhanced TRAIL-
induced apoptosis [40]. Therefore, our results suggest
that elimination of cFLIP itself as a single factor may not
be sufficient to fully restore the sensitivity to TRAIL-
induced apoptosis, and modulation(s) at the level of other
molecule(s) such as DR5 need to be involved.
Various chemotherapeutic drugs are known to trigger
intrinsic apoptotic pathway [41] and/or increase a sus-
ceptibility of mitochondria to apoptotic signals translo-
cated from DRs [25,42,43]. In our experiments we
detected an increase of caspase-2 activity that was previ-
ously shown as a critical component of DNA damage-
induced apoptotic cascade, being activated upstream of
mitochondria [44]. Role of caspase-2 as initiator caspase
was also observed in apoptosis triggered by other chemo-
therapeutic drugs [14,45]. In addition to acting as an initi-
ator caspase primarily activated in DR-mediated
apoptosis at the DISC level, caspase-8 has also been
reported to be activated by other caspases downstream of
mitochondria during drug-induced apoptosis [46-48].
This led us to investigate the role of mitochondria and the
ordering of caspase activation. Since z-VAD-fmk effi-
ciently blocked TRAIL and doxorubicin-induced cleavage
of caspase-2, -3, PARP, lamin A, apoptotic nuclear mor-
phology changes, but not generation of caspase-8 p41/43
kDa fragment, we suggested that the first caspase-8 cleav-
age step might occur prior to and independently on the
activation of other caspases. Moreover, our results dem-
onstrated that siRNA-mediated downregulation of cas-
pase-8 resulted in marked decrease of TRAIL and
doxorubicin-induced processing of caspase-2 and -3, and
overall apoptosis, while re-expression of caspase-8 fully
reverted the apoptotic phenotype. Furthermore, a rapid
processing of caspase-8 was a relatively early event in the
course of TRAIL and doxorubicin-induced apoptosis
compared to attenuated kinetics of mitochondrial events,
such as cytochrome c release. Therefore, we assume that
chemotherapy-mediated modulation of events leading to
caspase-8 activation following TRAIL treatment occurs
upstream of mitochondria and effector caspases.
As TRAIL by itself did not induce caspase-8 processing,
it is likely that the resistance to TRAIL-induced apoptosis
is regulated by protein(s) acting upstream of this mole-
cule. Here we demonstrated that doxorubicin was effi-
cient in sensitizing the cells to apoptotic effects of TRAIL
that was associated with significant increase of surface
and total DR5 level, activation of caspase cascade through
processing of caspase-8, specific cleavage of cFLIPL, and
decrease of cFLIPS. Cellular apoptosis was accompanied
by cleavage of Bid, Bax activation, decrease of MMP,
cytochrome  c  release, decrease of survivin level, and
effector caspase activation. Based on the caspase-8
siRNA approach and experiments with z-VAD-fmk we
concluded that combination of TRAIL and doxorubicin
facilitates caspase-8 processing primarily at the DISC
level rather than being secondary result of activation of
mitochondrial pathway and/or effector caspases. We sug-
gest the possibility of sensitization of SCLC cells to
T R A I L  b y  m o d u l a t i o n  o f  t h e  a p i c a l  e v e n t s  i n  T R A I L
apoptotic signaling at the level of surface DR5 and intrac-
ellular inhibitory molecules such as cFLIP.
In summary, although TRAIL monotherapy is com-
pletely inefficient in SCLC cells due to defects in initialVaculova et al. Molecular Cancer 2010, 9:87
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steps of the DR-mediated pathway, combined treatment
with TRAIL and conventional chemotherapeutic drugs,
such as doxorubicin and etoposide, might be a promising
therapeutic strategy for SCLC expressing caspase-8. Our
results showed that doxorubicin and etoposide signifi-
cantly sensitized these cells to TRAIL-induced apoptosis
by modulation of events that facilitate activation of cas-
pase-8. Our study highlights the potential applicability of
this combination in chemotherapy of SCLC.
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